We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cerulean’s CRLX101 Gets Orphan Drug Status for Ovarian Cancer
Cerulean’s CRLX101 Gets Orphan Drug Status for Ovarian Cancer
The FDA has granted Cerulean Pharma’s investigational nanoparticle drug conjugate CRLX101 orphan status for the treatment of relapsed ovarian cancer, guaranteeing the drugmaker seven years added exclusivity if the product is approved.